C12N 9/16
Acting on ester bonds
Official title: acting on ester bonds (3.1)
C12N9/16 (Acting on ester bonds) appears on 8,368 US grants and 15,250 published applications in this corpus.
Search patents in C12N- Granted patents
- 8,368
- Published applications
- 15,250
- Assignees
- 3,803
- Inventors
- 24,588
- Latest grant
- 6 Oct 2026
Filings by year
| Year | Granted patents | Published applications |
|---|---|---|
| 1976 | 3 | 0 |
| 1977 | 12 | 0 |
| 1978 | 26 | 0 |
| 1979 | 7 | 0 |
| 1980 | 5 | 0 |
| 1981 | 3 | 0 |
| 1982 | 8 | 0 |
| 1983 | 9 | 0 |
| 1984 | 7 | 0 |
| 1985 | 9 | 0 |
| 1986 | 5 | 0 |
| 1987 | 18 | 0 |
| 1988 | 18 | 0 |
| 1989 | 14 | 0 |
| 1990 | 20 | 0 |
| 1991 | 44 | 0 |
| 1992 | 43 | 0 |
| 1993 | 66 | 0 |
| 1994 | 62 | 0 |
| 1995 | 66 | 0 |
| 1996 | 83 | 0 |
| 1997 | 98 | 0 |
| 1998 | 172 | 0 |
| 1999 | 189 | 0 |
| 2000 | 159 | 0 |
| 2001 | 174 | 29 |
| 2002 | 173 | 252 |
| 2003 | 152 | 381 |
| 2004 | 136 | 297 |
| 2005 | 122 | 265 |
| 2006 | 163 | 233 |
| 2007 | 122 | 198 |
| 2008 | 124 | 182 |
| 2009 | 105 | 255 |
| 2010 | 141 | 283 |
| 2011 | 147 | 278 |
| 2012 | 159 | 301 |
| 2013 | 191 | 329 |
| 2014 | 225 | 395 |
| 2015 | 214 | 391 |
| 2016 | 263 | 480 |
| 2017 | 245 | 502 |
| 2018 | 290 | 663 |
| 2019 | 367 | 889 |
| 2020 | 465 | 987 |
| 2021 | 474 | 1092 |
| 2022 | 557 | 1170 |
| 2023 | 544 | 1306 |
| 2024 | 586 | 1571 |
| 2025 | 635 | 1416 |
| 2026 | 448 | 1105 |
By publication year. Applications have been published since 2001. 2026 runs to 8 Oct.
Subgroups
Granted patents
Recent patents
- Tumor-targeting Salmonella gallinarum strain and use thereof6 Oct 2026US 12,751,978 B2Industry Foundation of Chonnam National University
- Engineered meganucleases having specificity for a recognition sequence in the hydroxyacid oxidase 1 gene6 Oct 2026US 12,752,019 B2Precision BioSciences, Inc.
- Carboxylic acid esters of xylitol and process for enzymatically preparing same6 Oct 2026US 12,753,396 B2Evonik Operations GmbH
- Prime editor system for in vivo genome editing6 Oct 2026US 12,753,397 B2University of Massachusetts
- CRISPR-mediated directed codon re-write6 Oct 2026US 12,753,398 B2Limagrain Europe S.A.
- Humanized ace2-expressing transgenic mouse susceptible to sars-cov-2 virus infection and method for producing same8 Oct 2026US 2026/0305587 A1Seoul National University R&Db Foundation
- Enzymatic modification of galactolipids in food8 Oct 2026US 2026/0305624 A1International N&H Denmark Aps
- Methods of preventing on-target genotoxicity induced by nucleases8 Oct 2026US 2026/0306552 A1Chu De Bordeaux
- Methods of treating neurodegenerative disorders8 Oct 2026US 2026/0306669 A1
- Base editing approaches to treat abca4-associated stargardt disease8 Oct 2026US 2026/0306670 A1Massachusetts Eye and Ear Infirmary
Most cited
By later US patents
- CRISPR-Cas systems and methods for altering expression of gene products1,186US 8,697,359 B1Massachusetts Institute of Technology · 2014
- Engineering and optimization of systems, methods and compositions for sequence manipulation with functional domains568US 8,993,233 B2Massachusetts Institute of Technology · 2015
- CRISPR-Cas component systems, methods and compositions for sequence manipulation560US 8,795,965 B2Massachusetts Institute of Technology · 2014
- CRISPR-Cas component systems, methods and compositions for sequence manipulation529US 8,871,445 B2Massachusetts Institute of Technology · 2014
- Engineering and optimization of improved systems, methods and enzyme compositions for sequence manipulation489US 8,865,406 B2Massachusetts Institute of Technology · 2014